Bernd Bohmeier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bernd Bohmeier has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Adedolapo Olorunfemi
Center for Emerging and Re-emerging Infectious Diseases, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
1 shared publicationAdekunle Olowe
Center for Emerging and Re-emerging Infectious Diseases, Ladoke Akintola University of Technology, Ogbomoso, Nigeria
1 shared publicationAmy Gaye
Centre International de recherche, de Formation en Genomique Appliquee et de Surveillance Sanitaire (CIGASS), Dakar, Senegal
1 shared publication- Arsène Zongo
Unit for Public Health Laboratory Support, Centre for International Health Protection (ZIG), Robert Koch Institute, Berlin, Germany
1 shared publication Awa B. Deme
Centre International de recherche, de Formation en Genomique Appliquee et de Surveillance Sanitaire (CIGASS), Dakar, Senegal
1 shared publicationBassirou Ngom
Centre International de recherche, de Formation en Genomique Appliquee et de Surveillance Sanitaire (CIGASS), Dakar, Senegal
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 11 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 4218
Continental-scale genomic surveillance of Plasmodium falciparum malaria across sub-Saharan Africa with rapid nanopore sequencing
In sub-Saharan Africa, continental-scale genomic surveillance of Plasmodium falciparum malaria is needed to track the spread of drug and diagnostic resistance, as well as monitor parasite evolutionary responses to vaccine rollout. Yet continental-scale implementation is hindered by a lack of genomic approaches suitable for local laboratories, and the vastness of the continent. Here, we initiate a decentralised scale-up of P. falciparum genomic surveillance by locally sequencing and analysing 1065 samples across six African countries in one year. We achieve this with a novel nanopore sequencing protocol that is rapid (~5 hr) and cost-effective (<$25 USD/sample), providing surveillance of antimalarial drug resistance genes, hrp2/3 deletions, the vaccine target csp , and the polymorphic gene ama1 . We couple this to a laptop-based bioinformatics dashboard that runs offline and displays mapping and variant calling results in real-time. We demonstrate robust sequencing coverage across parasitemia levels and laboratories, accurate identification of antimalarial resistance markers and hrp2/3 deletions; and, with a novel variant caller, sensitive detection of mutations carried by minor clones. Our approach will accelerate genomic surveillance of P. falciparum malaria across sub-Saharan Africa at a time of urgent need.
- 11 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 4218
Top Cited PapersOpen AccessContinental-scale genomic surveillance of Plasmodium falciparum malaria across sub-Saharan Africa with rapid nanopore sequencing
In sub-Saharan Africa, continental-scale genomic surveillance of Plasmodium falciparum malaria is needed to track the spread of drug and diagnostic resistance, as well as monitor parasite evolutionary responses to vaccine rollout. Yet continental-scale implementation is hindered by a lack of genomic approaches suitable for local laboratories, and the vastness of the continent. Here, we initiate a decentralised scale-up of P. falciparum genomic surveillance by locally sequencing and analysing 1065 samples across six African countries in one year. We achieve this with a novel nanopore sequencing protocol that is rapid (~5 hr) and cost-effective (<$25 USD/sample), providing surveillance of antimalarial drug resistance genes, hrp2/3 deletions, the vaccine target csp , and the polymorphic gene ama1 . We couple this to a laptop-based bioinformatics dashboard that runs offline and displays mapping and variant calling results in real-time. We demonstrate robust sequencing coverage across parasitemia levels and laboratories, accurate identification of antimalarial resistance markers and hrp2/3 deletions; and, with a novel variant caller, sensitive detection of mutations carried by minor clones. Our approach will accelerate genomic surveillance of P. falciparum malaria across sub-Saharan Africa at a time of urgent need.